9 results on '"Hellamand, Pasoon"'
Search Results
2. ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis – Are they interchangeable?
- Author
-
Georgiadis, Stylianos, primary, Ørnbjerg, Lykke Midtbøll, additional, Michelsen, Brigitte, additional, Kvien, Tore K., additional, Di Giuseppe, Daniela, additional, Wallman, Johan K., additional, Závada, Jakub, additional, Provan, Sella A., additional, Kristianslund, Eirik Klami, additional, Rodrigues, Ana Maria, additional, Santos, Maria José, additional, Rotar, Žiga, additional, Pirkmajer, Katja Perdan, additional, Nordström, Dan, additional, Macfarlane, Gary J., additional, Jones, Gareth T., additional, van der Horst-Bruinsma, Irene, additional, Hellamand, Pasoon, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis:Results From the European Spondyloarthritis Research Collaboration Network
- Author
-
Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., van der Horst-Bruinsma, Irene E., Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., and van der Horst-Bruinsma, Irene E.
- Abstract
Objective Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management., Objective: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.
- Published
- 2024
4. Cut-Offs for Disease Activity States in Axial Spondylarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
- Author
-
Georgiadis, Stylianos, Ørnbjerg, Lykke Midtbøll, Michelsen, Brigitte, Kvien, Tore K., Di Giuseppe, Daniela, Wallman, Johan K., Závada, Jakub, Provan, Sella A., Kristianslund, Eirik Klami, Rodrigues, Ana Maria, Santos, Maria José, Rotar, Žiga, Pirkmajer, Katja Perdan, Nordström, Dan, Macfarlane, Gary J., Jones, Gareth T., van der Horst-Bruinsma, Irene, Hellamand, Pasoon, Østergaard, Mikkel, and Hetland, Merete Lund
- Published
- 2024
- Full Text
- View/download PDF
5. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
- Author
-
Hellamand, Pasoon, primary, van de Sande, Marleen G. H., additional, Ørnbjerg, Lykke M., additional, Klausch, Thomas, additional, Eklund, Kari K., additional, Relas, Heikki, additional, Santos, Maria J., additional, Vieira‐Sousa, Elsa, additional, Loft, Anne G., additional, Glintborg, Bente, additional, Østergaard, Mikkel, additional, Lindström, Ulf, additional, Wallman, Johan K., additional, Michelsen, Brigitte, additional, Fagerli, Karen M., additional, Castrejón, Isabel, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur J., additional, Vencovský, Jiří, additional, Nekvindová, Lucie, additional, Rotar, Žiga, additional, Tomšič, Matija, additional, Díaz‐González, Federico, additional, Kenar, Gökçe, additional, Tuğsal, Handan Y., additional, Iannone, Florenzo, additional, Ramonda, Roberta, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Nissen, Michael J., additional, Möller, Burkhard, additional, Hetland, Merete L., additional, and van der Horst‐Bruinsma, Irene E., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network
- Author
-
Hellamand, Pasoon, primary, van de Sande, Marleen, additional, Ørnbjerg, Lykke MIdtbøll, additional, Klausch, Thomas, additional, Nurmohamed, Michael T, additional, van Vollenhoven, Ronald F, additional, Nordström, Dan, additional, Hokkanen, Anna Mari, additional, Santos, Maria Jose, additional, Vieira-Sousa, Elsa, additional, Loft, Anne G, additional, Glintborg, Bente, additional, Hetland, Merete Lund, additional, Lindström, Ulf, additional, Wallman, Johan K, additional, Michelsen, Brigitte, additional, Klami Kristianslund, Eirik, additional, Ciurea, Adrian, additional, Nissen, Michael S, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Macfarlane, Gary J, additional, Rotariu, Ovidiu, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, Castrejon, Isabel, additional, Otero-Varela, Lucia, additional, Gudbjornsson, Bjorn, additional, Geirsson, Arni Jon, additional, Vencovský, Jiří, additional, Pavelka, Karel, additional, Gulle, Semih, additional, Zengin, Berrin, additional, Iannone, Florenzo, additional, Foti, Rosario, additional, Ostergaard, Mikkel, additional, and van der Horst-Bruinsma, Irene, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration
- Author
-
Linde, Louise; https://orcid.org/0000-0003-0863-1352, Ørnbjerg, Lykke M, Rasmussen, Simon H, Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K, Kvien, Tore K, Rodrigues, Ana M, Santos, Maria J, Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Macfarlane, Gary J, Heddle, Maureen, et al, Linde, Louise; https://orcid.org/0000-0003-0863-1352, Ørnbjerg, Lykke M, Rasmussen, Simon H, Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K, Kvien, Tore K, Rodrigues, Ana M, Santos, Maria J, Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Macfarlane, Gary J, Heddle, Maureen, and et al
- Abstract
BACKGROUND: In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs). METHODS: Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey. RESULTS: Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68-86%) compared to prior (50-79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale. CONCLUSION: Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.
- Published
- 2023
8. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis:Results from the EuroSpA Research Collaboration Network
- Author
-
Hellamand, Pasoon, Van De Sande, Marleen, Ørnbjerg, Lykke Midtbøll, Klausch, Thomas, Nurmohamed, Michael T., Van Vollenhoven, Ronald F., Nordström, Dan, Hokkanen, Anna Mari, Santos, Maria Jose, Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Hetland, Merete Lund, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Klami Kristianslund, Eirik, Ciurea, Adrian, Nissen, Michael S., Codreanu, Catalin, Mogosan, Corina, Macfarlane, Gary J., Rotariu, Ovidiu, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Otero-Varela, Lucia, Gudbjornsson, Bjorn, Geirsson, Arni Jon, Vencovský, Ji, Pavelka, Karel, Gulle, Semih, Zengin, Berrin, Iannone, Florenzo, Foti, Rosario, Ostergaard, Mikkel, Van Der Horst-Bruinsma, Irene, Hellamand, Pasoon, Van De Sande, Marleen, Ørnbjerg, Lykke Midtbøll, Klausch, Thomas, Nurmohamed, Michael T., Van Vollenhoven, Ronald F., Nordström, Dan, Hokkanen, Anna Mari, Santos, Maria Jose, Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Hetland, Merete Lund, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Klami Kristianslund, Eirik, Ciurea, Adrian, Nissen, Michael S., Codreanu, Catalin, Mogosan, Corina, Macfarlane, Gary J., Rotariu, Ovidiu, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Otero-Varela, Lucia, Gudbjornsson, Bjorn, Geirsson, Arni Jon, Vencovský, Ji, Pavelka, Karel, Gulle, Semih, Zengin, Berrin, Iannone, Florenzo, Foti, Rosario, Ostergaard, Mikkel, and Van Der Horst-Bruinsma, Irene
- Abstract
Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA patients initiating their first TNFi. Methods Data from axSpA patients initiating a TNFi in 1 of 15 registries within EuroSpA collaboration were pooled. We investigated the association of sex with treatment response using logistic regression. The primary outcome was clinically important improvement (CII) at 6 months according to Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (≥1.1 decrease). We adjusted for age, country and TNFi start year. A secondary outcome was retention rates over 24 months of follow-up assessed by Kaplan-Meier estimator. Results In total, 6451 axSpA patients with data on CII were assessed for treatment response; 2538 (39%) were women and 3913 (61%) were men. Women presented at baseline with lower CRP levels but had higher scores on patient-reported outcome measures. At 6 months, 53% of the women and 66% of the men had CII. Women had a lower relative risk of CII compared with men (0.81; 95% CI 0.77 to 0.84). This sex difference was similar in adjusted analysis (0.85; 95% CI 0.82 to 0.88). Retention rates were evaluated in 27 702 patients. The TNFi 6/12/24 months retention rates were significantly lower among women (79%/66%/53%) than men (88%/79%/69%). Conclusion Treatment response and retention rates are lower among women with axSpA initiating their first TNFi. Sex differences in treatment effectiveness were present regardless of the outcome measure used for treatment response, and differences in retention rates transpired early and increased as time progressed., Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA patients initiating their first TNFi. Methods Data from axSpA patients initiating a TNFi in 1 of 15 registries within EuroSpA collaboration were pooled. We investigated the association of sex with treatment response using logistic regression. The primary outcome was clinically important improvement (CII) at 6 months according to Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (≥1.1 decrease). We adjusted for age, country and TNFi start year. A secondary outcome was retention rates over 24 months of follow-up assessed by Kaplan-Meier estimator. Results In total, 6451 axSpA patients with data on CII were assessed for treatment response; 2538 (39%) were women and 3913 (61%) were men. Women presented at baseline with lower CRP levels but had higher scores on patient-reported outcome measures. At 6 months, 53% of the women and 66% of the men had CII. Women had a lower relative risk of CII compared with men (0.81; 95% CI 0.77 to 0.84). This sex difference was similar in adjusted analysis (0.85; 95% CI 0.82 to 0.88). Retention rates were evaluated in 27 702 patients. The TNFi 6/12/24 months retention rates were significantly lower among women (79%/66%/53%) than men (88%/79%/69%). Conclusion Treatment response and retention rates are lower among women with axSpA initiating their first TNFi. Sex differences in treatment effectiveness were present regardless of the outcome measure used for treatment response, and differences in retention rates transpired early and increased as time progressed.
- Published
- 2023
9. Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
- Author
-
Hellamand P, van de Sande MGH, Nurmohamed MT, van Vollenhoven RF, Hollick RJ, Rotariu O, Rotar Z, Pirkmajer KP, Nordström D, Hokkanen AM, Michelsen B, Kvien TK, Glintborg B, Hetland ML, Østergaard M, Loft AG, Pavelka K, Zavada J, Castrejon I, Otero-Varela L, Gudbjornsson B, Palsson O, Olofsson T, Wallman JK, Ciurea A, Nissen MJ, Yildirim TD, Onen F, Codreanu C, Mogosan C, Santos MJ, Vieira-Sousa E, Iannone F, Frediani B, Ørnbjerg LM, Twisk JWR, and van der Horst-Bruinsma IE
- Abstract
Objectives: To investigate sex differences in patient-reported outcome measures (PROMs) among axSpA patients initiating their first TNFi and identify factors contributing to these disparities over the follow-up., Methods: Data were included from 15 EuroSpA registries and consisted of axSpA patients initiating their first TNFi, with ≥2 measurements for each analysed PROM (BASDAI and BASFI, scale 0-100) taken at any time point. Linear mixed models were employed to analyse sex differences in PROMs over 24 months and to evaluate how baseline characteristics were related to the observed sex differences., Results: We analysed 13 102 (38% women) in the BASDAI analyses and 10 623 (38% women) in the BASFI analyses. At follow-up, mean sex differences in BASDAI increased from 4.3 units at baseline (95% CI, 3.5-5.1)-8.0 (7.2-8.8) at 6 months, and in BASFI from 2.2 (1.4-3.1)-4.6 (3.6-5.5), with consistently worse scores in women. Baseline characteristics could not substantially account for the observed sex differences over time; however, the magnitude of the sex differences was reduced by HLA-B27 positivity, longer disease duration, and increased CRP levels, but increased by TNFi initiation in later years and peripheral arthritis., Conclusion: In axSpA patients initiating their first TNFi, baseline sex differences in BASDAI and BASFI increased two-fold after 6 months of treatment and persisted thereafter, with worse scores in women. Several baseline characteristics moderated the sex differences, though none could fully account for them. These findings improve our understanding of sex differences and underscore their importance in axSpA., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.